Cantargia publishes interim report for January – September 2016

Cantargia AB (“Cantargia”) interim report for January – September 2016 is available on the company website (www.cantargia.com/Investors/Reports).

Significant events in the third quarter

The US patent office granted two of Cantargias patent applications; i.e. the application for the use of IL1RAP as target molecule for antibody-based treatment of solid tumors and as well as the application for IL1RAP as a target for antibody-based treatment of acute lymphoblastic leukemia (ALL).

Cantargia raised SEK 250,212.50 through the exercise of warrants of series 2011/2016 by Agneta Svedberg, the former CEO of Cantargia.

New results from studies using Cantargia’s antibodies for treatment of chronic myeloid leukemia (CML) in preclinical models was published in the respected scientific journal Blood.

Cantargia presented a more aggressive development strategy, under which the company will expand its coming clinical study to also cover combination therapies. The development strategy will require additional capital, and the company is therefore looking to raise approximately SEK 80 million.

Significant events after the end of the period 

A third party filed an opposition to the patent approval for antibody treatment of solid tumours which Cantargia received from the European Patent Office in January 2016. The Company believes the opposition is groundless.

Cantargia presented new data from preclinical studies using CAN04 in non-small cell lung cancer in the form of a poster at the international Protein & Antibody Engineering Summit (“PEGS”). The presentation is available on Cantargia’s website, www.cantargia.com. The company will also present data from studies using Cantargia’s antibodies in chronic myeloid leukemia at the scientific conference arranged by the American Society of Hematology on 3–6 December 2016.

Warrants of series TO 2 and series TO 4 were exercisable during the period September/October 2016. Over 98 per cent of the warrants were exercised, raising around SEK 24.6 million for the company.

Financial information

Nine months (1 Jan 2016 – 30 Sep 2016)

Other operating revenue was kSEK 0 (0).

Earnings after financial items were kSEK -28,509 (-12,187).

Earnings per share were approximately SEK -1.61 (-0.91).

The equity/assets ratio was around 76 (89) per cent compared with the beginning of the year.

Third quarter (1 Jul 2016 – 30 Sep 2016)

Other operating revenue was kSEK 0 (0).

Earnings after financial items were kSEK -12,486 (-3,127).

Earnings per share were approximately SEK -0.71 (-0.23).

Definitions

Earnings per share: Profit for the period divided by 17,679,384 shares as at 30 September 2016.

Equity/assets ratio: Equity divided by total capital.

Unless otherwise indicated, figures in parentheses refer the same period in the previous year.

For further information, contact
Göran Forsberg, CEO
Tel.: +46 (0)046-275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Adviser: Sedermera Fondkommission

This information is of such a nature that Cantargia is obliged to publish it in accordance with the EU's regulation on market abuse. Information has been provided, through the agency of the above contact person, for publication on 21 November 2016 at 08.30.

---